Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Calcitonin-Induced Hypocalcaemia as a Possible Index of Osteoclastic Activity in Patients with Chronic Renal Failure

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          It has been suggested that the intensity of hypocalcaemic response to the administration of calcitonin may reflect the degree of osteoclastic activity and thus the state of the parathyroid function. We have performed the calcitonin test in 14 healthy volunteers and in 17 patients with chronic renal failure undergoing haemodialysis, The test involved the intramuscular injection of 100 MRC units of synthetic salmon calcitonin, serum calcium being determined before and after 5 h of the injections of the hormone. In 7 of the patients, the test was repeated using intranasal administration by means of a spray of calcitonin. In renal patients, serum calcium fell from 9.73 ± 0.76 to 7.88 ± 1.01 mg/dl (1.85 ± 0.67 mg/dl). In the control group, serum calcium fell from 9.51 ± 0.56 to 8.89 ± 0.34 mg/dl (0.62 ± 0.35 mg/dl). The calcium fall in renal patients was significantly greater than in the control group (p < 0.001). In patients there was a statistically significant correlation between the fall in serum calcium and the level of alkaline phosphatase, but no with the serum concentration of immunoreactive parathormone (C-Terminal). After intranasal calcitonin, serum calcium fell from 9.81 ± 0.55 to 8.83 ± 0.72 mg/dl (1.42 ± 0.42 mg/dl), a reduction comparable to that obtained after the intramuscular injection of the hormone in the same patients (1.84 ± 0.69 mg/dl). These results provide evidence of an increase in osteoclastic activity in chronic renal failure, perhaps reflecting parathyroid hyperfunction. The lack of correlation between serum calcium fall and the levels of parathormone probably means that there is an inadequancy of the C-terminal radioimmunoassay of this hormone in renal failure. The calcitonin test may be an usuful index of bone state in uraemia, in addition to alkaline phosphatase, osteocalcin, and immunoreactive parathormone. The intranasal route has been effective, and it should make the test easier to perform; however, it is still in an experimental phase.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1987
          1987
          05 December 2008
          : 47
          : 4
          : 241-245
          Affiliations
          aServicio de Nefrología, Hospital General de Galicia, Facultad de Medicina, Universidad de Santiago de Compostela, España; bSector de Osteopatías, Hospital Clínico de San Carlos, Facultad de Medicina, Universidad Complutense, Madrid, España
          Article
          184517 Nephron 1987;47:241–245
          10.1159/000184517
          3696325
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Categories
          Original Paper

          Comments

          Comment on this article